Ultragenyx's Gene Therapy DTX301 Achieves Key Trial Goal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Should l Buy RARE?
Source: seekingalpha
- Clinical Trial Success: Ultragenyx's gene therapy candidate DTX301 achieved its primary goal in a late-stage trial for the most common urea cycle disorder, with 36-week data showing an ~18% reduction in 24-hour plasma ammonia levels in treated patients, indicating statistical significance and clinical relevance.
- Positive Patient Response: Among nine patients with abnormal ammonia levels, eight swiftly returned to normal after DTX301 treatment, suggesting the therapy's potential to improve patient health outcomes and possibly transform the treatment landscape for OTC deficiency.
- Safety Assessment: While only one patient in the DTX301 group discontinued the trial, compared to two in the placebo group, which included one death, this indicates a relatively higher safety profile for DTX301, with only one hospitalization event for hyperammonemic crises in the treatment group.
- Ongoing Multinational Trial: The trial, involving 37 patients across 10 countries, is set to report secondary endpoint data on the treatment burden of DTX301 in H1 2027, further validating its clinical application potential and possibly opening new market opportunities for Ultragenyx.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RARE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RARE
Wall Street analysts forecast RARE stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 22.210
Low
35.00
Averages
61.65
High
120.00
Current: 22.210
Low
35.00
Averages
61.65
High
120.00
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ultragenyx's Gene Therapy DTX301 Achieves Key Trial Goal
- Clinical Trial Success: Ultragenyx's gene therapy candidate DTX301 achieved its primary goal in a late-stage trial for the most common urea cycle disorder, with 36-week data showing an ~18% reduction in 24-hour plasma ammonia levels in treated patients, indicating statistical significance and clinical relevance.
- Positive Patient Response: Among nine patients with abnormal ammonia levels, eight swiftly returned to normal after DTX301 treatment, suggesting the therapy's potential to improve patient health outcomes and possibly transform the treatment landscape for OTC deficiency.
- Safety Assessment: While only one patient in the DTX301 group discontinued the trial, compared to two in the placebo group, which included one death, this indicates a relatively higher safety profile for DTX301, with only one hospitalization event for hyperammonemic crises in the treatment group.
- Ongoing Multinational Trial: The trial, involving 37 patients across 10 countries, is set to report secondary endpoint data on the treatment burden of DTX301 in H1 2027, further validating its clinical application potential and possibly opening new market opportunities for Ultragenyx.
See More
Ultragenyx Reports Positive Phase 3 Results for DTX301 Gene Therapy
- Clinical Trial Results: Ultragenyx's Phase 3 Enh3ance study of DTX301 demonstrated a statistically significant 18% reduction in 24-hour plasma ammonia levels at Week 36, indicating potential effectiveness for the rare metabolic disorder OTC deficiency.
- Patient Improvement: Among patients treated with DTX301, 71% reported being 'much improved' in overall OTC symptoms at Week 24, compared to none in the placebo group, highlighting the therapy's significant impact on quality of life.
- Treatment Tolerability: DTX301 was generally well tolerated, with most side effects classified as mild to moderate and manageable with steroids, contrasting sharply with the placebo group, which faced five hyperammonemia crises requiring hospitalization.
- Future Research Directions: The study will continue to assess treatment burden reduction over 64 weeks, with data expected in the first half of 2027, further validating the long-term efficacy and safety of DTX301.
See More
Ultragenyx Securities Class Action Reminder
- Filing Deadline: ClaimsFiler reminds investors that those who purchased Ultragenyx shares between August 3, 2023, and December 26, 2025, must file lead plaintiff applications by April 6, 2026, to protect their rights in the class action lawsuit.
- Legal Allegations: Ultragenyx and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which prevented investors from making informed decisions during a critical time.
- Stock Price Plunge: Following the announcement on December 26, 2025, that setrusumab (UX143) failed to show a statistically significant reduction in fracture rates, Ultragenyx's stock price plummeted by approximately 42%, from $34.19 to $19.72, severely impacting the company's market value and investor confidence.
- Legal Assistance Info: Investors can visit ClaimsFiler for legal consultation, where Kahn Swick & Foti, LLC offers free case evaluations to help investors understand their legal options and participate in the lawsuit.
See More
Ultragenyx Pharmaceutical Faces Class Action Lawsuit
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Ultragenyx Pharmaceutical and certain officers, seeking damages for investors who purchased securities between August 3, 2023, and December 26, 2025, reflecting significant investor dissatisfaction with the company's transparency.
- Allegations of False Statements: The complaint alleges that throughout the class period, defendants made false and/or misleading statements and failed to disclose risks associated with their Phase III Orbit study, potentially misleading investors about the company's prospects and impacting stock price and market confidence.
- Investor Action Deadline: Affected investors have until April 6, 2026, to request to be appointed as lead plaintiff, which may encourage more investors to take action and increase participation in the lawsuit, highlighting the urgency of the situation.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC is a reputable firm in securities fraud class actions, having recovered hundreds of millions for investors nationwide, demonstrating its strong capability and influence in protecting investor rights.
See More
Ultragenyx Pharmaceutical Class Action Lawsuit Notification
- Lawsuit Background: Kahn Swick & Foti LLC informs investors of a class action lawsuit against Ultragenyx Pharmaceutical for alleged securities fraud occurring between August 3, 2023, and December 26, 2025, aimed at recovering losses for affected investors.
- Study Failure Impact: On December 26, 2025, Ultragenyx announced that its Phase 3 Orbit and Cosmic studies for setrusumab failed to show a statistically significant reduction in annualized fracture rates for osteogenesis imperfecta patients, prompting the company to evaluate significant expense reductions.
- Stock Price Plunge: Following the lawsuit announcement, Ultragenyx's stock price plummeted approximately 42%, from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025, indicating a pessimistic market outlook on the company's future.
- Investor Action Recommendation: Affected investors have until April 6, 2026, to request to be appointed as lead plaintiff, although they can still share in any recovery without serving as lead plaintiff, highlighting the legal process's potential impact on investors.
See More
Ultragenyx Faces Class Action Lawsuit Amid Significant Stock Decline
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Ultragenyx Pharmaceutical, alleging securities fraud and unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by April 6, 2026.
- Stock Price Plunge: Following disappointing clinical trial updates on July 10, 2025, Ultragenyx's stock fell by 25.11%, losing $10.41 per share to close at $31.04, reflecting significant market concerns regarding its developmental prospects.
- Trial Failures Announced: On December 29, 2025, Ultragenyx disclosed that its Phase III Orbit and Cosmic studies failed to achieve statistical significance, causing a further 42.32% drop in stock price, equating to a $14.47 loss per share, closing at $34.19, which heightened investor anxiety.
- Potential Legal Ramifications: The class action lawsuit could expose Ultragenyx to substantial financial liabilities, impacting its future fundraising capabilities and market credibility, posing significant challenges to the company's long-term growth trajectory.
See More
Ultragenyx's Gene Therapy DTX301 Achieves Key Trial Goal
- Clinical Trial Success: Ultragenyx's gene therapy candidate DTX301 achieved its primary goal in a late-stage trial for the most common urea cycle disorder, with 36-week data showing an ~18% reduction in 24-hour plasma ammonia levels in treated patients, indicating statistical significance and clinical relevance.
- Positive Patient Response: Among nine patients with abnormal ammonia levels, eight swiftly returned to normal after DTX301 treatment, suggesting the therapy's potential to improve patient health outcomes and possibly transform the treatment landscape for OTC deficiency.
- Safety Assessment: While only one patient in the DTX301 group discontinued the trial, compared to two in the placebo group, which included one death, this indicates a relatively higher safety profile for DTX301, with only one hospitalization event for hyperammonemic crises in the treatment group.
- Ongoing Multinational Trial: The trial, involving 37 patients across 10 countries, is set to report secondary endpoint data on the treatment burden of DTX301 in H1 2027, further validating its clinical application potential and possibly opening new market opportunities for Ultragenyx.
See More
Ultragenyx Reports Positive Phase 3 Results for DTX301 Gene Therapy
- Clinical Trial Results: Ultragenyx's Phase 3 Enh3ance study of DTX301 demonstrated a statistically significant 18% reduction in 24-hour plasma ammonia levels at Week 36, indicating potential effectiveness for the rare metabolic disorder OTC deficiency.
- Patient Improvement: Among patients treated with DTX301, 71% reported being 'much improved' in overall OTC symptoms at Week 24, compared to none in the placebo group, highlighting the therapy's significant impact on quality of life.
- Treatment Tolerability: DTX301 was generally well tolerated, with most side effects classified as mild to moderate and manageable with steroids, contrasting sharply with the placebo group, which faced five hyperammonemia crises requiring hospitalization.
- Future Research Directions: The study will continue to assess treatment burden reduction over 64 weeks, with data expected in the first half of 2027, further validating the long-term efficacy and safety of DTX301.
See More
Ultragenyx Securities Class Action Reminder
- Filing Deadline: ClaimsFiler reminds investors that those who purchased Ultragenyx shares between August 3, 2023, and December 26, 2025, must file lead plaintiff applications by April 6, 2026, to protect their rights in the class action lawsuit.
- Legal Allegations: Ultragenyx and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which prevented investors from making informed decisions during a critical time.
- Stock Price Plunge: Following the announcement on December 26, 2025, that setrusumab (UX143) failed to show a statistically significant reduction in fracture rates, Ultragenyx's stock price plummeted by approximately 42%, from $34.19 to $19.72, severely impacting the company's market value and investor confidence.
- Legal Assistance Info: Investors can visit ClaimsFiler for legal consultation, where Kahn Swick & Foti, LLC offers free case evaluations to help investors understand their legal options and participate in the lawsuit.
See More
Ultragenyx Pharmaceutical Faces Class Action Lawsuit
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Ultragenyx Pharmaceutical and certain officers, seeking damages for investors who purchased securities between August 3, 2023, and December 26, 2025, reflecting significant investor dissatisfaction with the company's transparency.
- Allegations of False Statements: The complaint alleges that throughout the class period, defendants made false and/or misleading statements and failed to disclose risks associated with their Phase III Orbit study, potentially misleading investors about the company's prospects and impacting stock price and market confidence.
- Investor Action Deadline: Affected investors have until April 6, 2026, to request to be appointed as lead plaintiff, which may encourage more investors to take action and increase participation in the lawsuit, highlighting the urgency of the situation.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC is a reputable firm in securities fraud class actions, having recovered hundreds of millions for investors nationwide, demonstrating its strong capability and influence in protecting investor rights.
See More
Ultragenyx Pharmaceutical Class Action Lawsuit Notification
- Lawsuit Background: Kahn Swick & Foti LLC informs investors of a class action lawsuit against Ultragenyx Pharmaceutical for alleged securities fraud occurring between August 3, 2023, and December 26, 2025, aimed at recovering losses for affected investors.
- Study Failure Impact: On December 26, 2025, Ultragenyx announced that its Phase 3 Orbit and Cosmic studies for setrusumab failed to show a statistically significant reduction in annualized fracture rates for osteogenesis imperfecta patients, prompting the company to evaluate significant expense reductions.
- Stock Price Plunge: Following the lawsuit announcement, Ultragenyx's stock price plummeted approximately 42%, from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025, indicating a pessimistic market outlook on the company's future.
- Investor Action Recommendation: Affected investors have until April 6, 2026, to request to be appointed as lead plaintiff, although they can still share in any recovery without serving as lead plaintiff, highlighting the legal process's potential impact on investors.
See More
Ultragenyx Faces Class Action Lawsuit Amid Significant Stock Decline
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Ultragenyx Pharmaceutical, alleging securities fraud and unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by April 6, 2026.
- Stock Price Plunge: Following disappointing clinical trial updates on July 10, 2025, Ultragenyx's stock fell by 25.11%, losing $10.41 per share to close at $31.04, reflecting significant market concerns regarding its developmental prospects.
- Trial Failures Announced: On December 29, 2025, Ultragenyx disclosed that its Phase III Orbit and Cosmic studies failed to achieve statistical significance, causing a further 42.32% drop in stock price, equating to a $14.47 loss per share, closing at $34.19, which heightened investor anxiety.
- Potential Legal Ramifications: The class action lawsuit could expose Ultragenyx to substantial financial liabilities, impacting its future fundraising capabilities and market credibility, posing significant challenges to the company's long-term growth trajectory.
See More
